Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer

M Labrie, JS Brugge, GB Mills… - Nature reviews Cancer, 2022 - nature.com
Normal cells explore multiple states to survive stresses encountered during development
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …

Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies

J Gao, HA Pickett - Nature Reviews Cancer, 2022 - nature.com
Cancer cells establish replicative immortality by activating a telomere-maintenance
mechanism (TMM), be it telomerase or the alternative lengthening of telomeres (ALT) …

Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments

HYK Yip, A Papa - Cells, 2021 - mdpi.com
Molecular alterations in cancer genes and associated signaling pathways are used to inform
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …

Targeted therapy and mechanisms of drug resistance in breast cancer

B Kinnel, SK Singh, G Oprea-Ilies, R Singh - Cancers, 2023 - mdpi.com
Simple Summary Internationally, in women, breast cancer (BC) is the most common cancer
type and is the leading cause of cancer-related death. There are two main histological …

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment

S Li, L Wang, Y Wang, C Zhang, Z Hong… - Journal of Hematology & …, 2022 - Springer
Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor
genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and …

ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib

Z Wilson, R Odedra, Y Wallez, PWG Wijnhoven… - Cancer research, 2022 - AACR
AZD6738 (ceralasertib) is a potent and selective orally bioavailable inhibitor of ataxia
telangiectasia and Rad3-related (ATR) kinase. ATR is activated in response to stalled DNA …

PARP inhibitors in metastatic prostate cancer: evidence to date

E Nizialek, ES Antonarakis - Cancer management and research, 2020 - Taylor & Francis
Poly (ADP-ribose) polymerase inhibitors (PARPi) are a unique class of antineoplastic agents
that function by inducing synthetic lethality. Synthetic lethality occurs when PARPi and either …

RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors

A Roulston, M Zimmermann, R Papp, A Skeldon… - Molecular cancer …, 2022 - AACR
Ataxia telangiectasia and Rad3-related (ATR) kinase protects genome integrity during DNA
replication. RP-3500 is a novel, orally bioavailable clinical-stage ATR kinase inhibitor …

cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy

ZJ Long, JD Wang, JQ Xu, XX Lei, Q Liu - Molecular Therapy, 2022 - cell.com
The correct duplication and transfer of genetic material to daughter cells is the major event of
cell division. Dysfunction of DNA replication or chromosome segregation presents …

Targeting DNA damage response in prostate and breast cancer

AM Wengner, A Scholz, B Haendler - International journal of molecular …, 2020 - mdpi.com
Steroid hormone signaling induces vast gene expression programs which necessitate the
local formation of transcription factories at regulatory regions and large-scale alterations of …